200006046-7 1/pos

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 239/94, A61K 31/505 — A1

(11) International Publication Number: **WO 99/55683**

(43) International Publication Date: 4 November 1999 (04.11.99)

(21) International Application Number: PCT/IB99/00612

(22) International Filing Date: 8 April 1999 (08.04.99)

(30) Priority Data:
60/083,441 29 April 1998 (29.04.98) US

(71) Applicant *(for all designated States except US)*: PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: ALLEN, Douglas, John, Meldrum [US/US]; 549 Ocean Avenue, New London, CT 06320 (US). NORRIS, Timothy [GB/US]; 27 Friar Tuck Drive, Gales Ferry, CT 06335 (US). RAGGON, Jeffrey, William [US/US]; 48 Teecomwas Drive, Uncasville, CT 06382 (US). SANTAFIANOS, Dinos, Paul [GB/US]; 93 Gerald Drive, Manchester, CT 06040 (US). SHANKER, Ravi, Mysore [IN/US]; Apartment #816, 600 Meridian Street Extension, Groton, CT 06340 (US).

(74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE MESYLATE ANHYDRATE AND MONOHYDRATE

(57) Abstract

The present invention relates to the anhydrous and hydrate forms of N- (3-ethynylphenyl)-6,7-bis (2-methoxyethoxy)4-quinazolinamine mesylate. The invention also relates to pharmaceutical compositions containing N- (3-ethynylphenyl)-6,7- bis(2-methoxyethoxy) -4-quinazolinamine mesylate and to methods of treating hyperproliferative disorders, such as cancer, by administering N- (3-ethynylphenyl)-6,7- bis(2-methoxyethoxy)-4- quinazolinamine mesylate.